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Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. We performed shotgun liquid chromatography
(LC)/tandem mass spectrometry (MS/MS) analysis on pooled protein extracts from patients with PTC and compared the results
with those from normal thyroid tissue validated by real-time (RT) PCR and immunohistochemistry (IHC). We detected 524 types
of protein in PTC and 432 in normal thyroid gland. Among these proteins, 145 were speciﬁc to PTC and 53 were speciﬁc to normal
thyroid gland. We have also identiﬁed two important new markers, nephronectin (NPNT) and malectin (MLEC). Reproducibility
wasconﬁrmedwithseveralknownmarkers,buttheoneoftwonewcandidatemarkerssuchasMLECdidnotshowlargevariations
in expression levels. Furthermore, IHC conﬁrmed the overexpression of both those markers in PTCs compared with normal
surrounding tissues. Our protein data suggest that NPNT and MLEC could be a characteristic marker for PTC.
1.Introduction
Papillary thyroid carcinoma (PTC) is the most common
form of the follicular-cell-derived carcinomas and comprises
three quarters of all newly diagnosed thyroid cancers [1].
PTC is derived from the follicular cells. These cells tend to
concentrate iodine and secrete thyroglobulin. As a result,
surveillance and detection of recurrence can be relatively
straightforward. The prognosis for PTC is usually excellent
(reviewed in [2]).
Over the past 10–15 years, several candidate genes have
been studied in the development of diﬀerent types of thyroid
cancer (e.g., TSH receptor, RET/PTC, Ras, BRAF, and p53)
[3–5]. These genes have been evaluated in thyroid cancer
based on what was known or other cancers or based on what
was expected from normal cell signaling (protooncogenes).
Recentstudiesusinggenearraytechnologyhaveattemptedto
use a hypothesis-generating approach to understand thyroid
neoplasms [6–8], but these studies rely on mRNA diﬀerences
that may not be related to signiﬁcant biologic processes.
mRNAdiﬀerencesdonotnecessarilyreﬂectdiﬀerencesatthe
protein level, and these RNA-based studies fail to identify
protein variants and posttranslational modiﬁcations that
aﬀect the tumor biology.
Proteomics is the name given to a set of analytical strate-
gies that can simultaneously identify and quantify thousands
of protein components in a biological sample [9]. There
is, however, no single approach that optimally meets this
demanding objective; instead, several complementary tech-
nologies have emerged, each oﬀering distinctive strengths2 Journal of Thyroid Research
Table 1: Clinical details of analyzed tissue samples.
No. Age
(yr) Gender Possible
PTC-subtype Proteomics RT-
PCR IHC
1 49 F Common type + + +
2 41 F Common type + + +
3 28 F Common type + + +
4 43 F Common type − ++
F: Female; PTC: papillary thyroid cancer; IHC: Immunohistochemistry; −:
not tested.
and weaknesses. These approaches are now facilitating new
biomarker discoveries in many areas of medicine. Studies
of the thyrocyte and thyroid cancer cell proteome are in
their infancy compared with studies of the genome and
transcriptome [9].
Weemployednanoﬂowliquidchromatographyandmass
spectrometry, followed by protein identiﬁcation by tandem
massspectrometry(LC/MS/MS)togainabetterunderstand-
ing of thyroid cancer and the unique alterations that are
characteristic of PTC. This technique provides an accurate
quantitative comparison of two groups of samples, allowing
the identiﬁcation of proteins whose levels diﬀer signiﬁcantly
between the two conditions. Using this approach, we have
identiﬁed novel diﬀerentially expressed proteins that may
provide insights into diagnosis, prognosis, and therapeutic
targetsforpatientswiththyroidneoplasms,aswellasintothe
underlying pathophysiology of thyroid tumor development
and progression.
2.MaterialsandMethods
2.1. Ethics Statement. The research protocol was approved
by the Ethic Committee of the Showa University Hospital,
andeachsubjectsignedtheinformedconsentformapproved
by the Institutional Review Board at the Showa University
Hospital.
2.2. Thyroid Tissue Samples. Tumor and matched normal
thyroid tissue was collected from four patients undergoing
surgeryforPTC.Specimens(100–500mg)fromeachpatient,
veriﬁed by histopathology, were snap frozen after conﬁr-
mation of tissue type. Tissue samples were collected from
women aged 28–49 years with no evidence of chronic lym-
phocytic thyroiditis in an attempt to minimize diﬀerences
due to gender, menopausal status, and autoimmune thyroid
disease. Unaﬀected (normal) thyroid tissue was deﬁned as
tissueadjacenttothesiteofthelesionwithnohistologicsigns
of abnormal pathology. Normal tissue was collected from
each patient undergoing surgery for PTC so that the biologic
variability in protein expression in a region proximate to
pathology could be assessed. All cases were analyzed by real-
time (RT) PCR analysis and immunohistochemistry (IHC),
whileLC/MS/MSwasappliedon3outof4cases.Theclinical
details of patients are summarized in Table 1.
2.3. Peptide Extraction for LC/MS/MS Analysis. Proteins
from samples for LC/MS/MS were extracted using 10μL
of 8M Urea solution with an ultrasonic homogenizer.
After homogenization, 90μL of 90% 100mM Ammonium
Bicarbonate Buﬀer (ABB: pH 8.0)/10% Acetonitrile were
added, followed by addition of 4μL of 100mM dithiothreitol
in ABB. Samples were incubated at 37◦Cf o r6 0 m i na n d
were cooled at room temperature. Next, 10μL of 100mM
iodoacetamide in ABB was added, and samples were incu-
bated at 37◦C for 30min in the dark. Finally, proteins in
the samples were digested with trypsin (15–18 units) by
overnight incubation at 37◦C. After extraction, all samples
were stored at −20◦C until LC/MS/MS analysis.
2.4. Shotgun Liquid Chromatography (LC)/Tandem Mass
Spectrometry (MS/MS). Peptide-mixture samples processed
from each tissue were used for nanoﬂow reverse phase liquid
chromatography followed by tandem MS, using an LTQ
linear ion-trap mass spectrometer (Thermo Fischer, San
Jose, CA). The capillary reverse phase HPLC-MS/MS system
(ZAPLOUS System; AMR, Tokyo, Japan) was composed of
a Paradigm MS4 dual solvent delivery system (Michrom
BioResources,Auburn, CA), an HTCPAL autosampler(CTC
Analytics, Zwingen, Switzerland), and Finnigan LTQ linear
ion-trap mass spectrometers (ITMS; Thermo Fischer, San
Jose,CA)equippedwithanXYZnanoelectrosprayionization
(NSI) source (AMR, Tokyo, Japan).
All samples were evaporated, and peptides were redis-
solved with MS-grade water containing 0.1% triﬂuoroacetic
acid and 2% acetonitrile (solvent A). Aliquots of 10μL
(equivalent to 1μg of protein) were automatically injected
into a peptide Cap-trap column (Michrom BioResources)
attached to an injector valve for desalinating and concentrat-
ing peptides. After washing the trap with solvent A, peptides
wereloadedontoaseparationcapillaryreversephasecolumn
(Mono Cap 150 × 0.2mm; GL Sciences, Tokyo, Japan)
by switching the valve. The eluents used were: A, 98%
H2O/2% acetonitrile/0.1% formic acid; B, 10% H2O/90%
acetonitrile/0.1% formic acid. The column was developed at
aﬂowrateofapproximately1μL/minwiththeconcentration
gradient of acetonitrile, as follows: ﬁrst, from 5% B to 55% B
in100min,thenfrom55%Bto95%Bin1min,maintenance
at 95% B for 9min, then from 95% B to 5% B in 3min, and
ﬁnally reequilibration with 5% B for 15min.
Eﬄuents were introduced into the mass spectrometer
via the NSI interface, which had a separation column outlet
connected directly with an NSI needle (150-μm OD/20-μm
ID FortisTip; OmniSeparo-TJ, Hyogo, Japan). ESI voltage
was 2.0kV, and the transfer capillary of the LTQ inlet was
heated at 200◦C. No sheath or auxiliary gas was used. The
mass spectrometer was operated in a z range of 450–1800
in a data-dependent acquisition mode, in which detecting
the most abundant ions at a retention time automatically
acquires MS/MS scans for those ions under the control of
Xcalibur software (Thermo Fischer) with an isolation width
of m/z 2.0 and a collisional activation amplitude of 35%.
Full-scan MS used enhanced/centroid mode, and sequential
MS/MSusednormal/centroidmode,withdynamicexclusion
capability, which allows sequential acquisition of MS/MSJournal of Thyroid Research 3
of abundant ions in the order of their intensities with an
exclusion duration of 1.0min and exclusion mass widths of
−1 and +2Da. The trapping time was 50ms using auto gain
control.
All MS/MS spectral data were searched against the Swis-
sProt 57.3 Homo sapiens database (468,851 entries) using
Mascot (version 2.1.04, Matrix Science, London, UK), in
which the peptide and fragment mass tolerances were 2.0Da
and 0.8Da, respectively. For variable peptide modiﬁcations,
methionine oxidation and carbamidomethyl (Cys) were
takenintoaccount.AP valuelessthan0.05wasconsideredto
indicate a statistically signiﬁcant diﬀerence, and the expected
score cut-oﬀ was 0.05. Reported results were obtained from
triplicate LC-MS runs for each sample with all peptide hits
included. Unique peptides and proteins were determined
by following proteomics guidelines. Relative abundances of
identiﬁed proteins were also obtained using the normalized
spectral abundance factor (NSAF) introduced by Kawamura
et al. and Zybailov et al. [10, 11].
2.5. Laser Microdissection and Semiquantitative Real-Time
PCR. Tumor cells of PTC and follicular epithelium of
normal thyroid tissue (periphery of PTC area) were collected
from frozen sections by laser microdissection. Total RNA
was extracted from each population of laser-microdissected
cells using an RNeasy Plus Micro kit (QIAGEN, Valencia,
CA) according to the manufacturer’s instructions. Reverse
transcription was carried out in 20-μL volumes using a High
Capacity RNA to cDNA MasterMix (Applied Biosystems,
Carlsbad, CA).
PCR was performed using an ABI PRISM 7500 Sequence
Detection System (Applied Biosystems), and analysis was
carried out using the sequence detection software supplied
with the instrument. Each reaction mixture contained
10μL of TaqMan Gene Expression Master Mix (Applied
Biosystems), 1μL of TaqMan Gene Expression Assay primer
(Applied Biosystems), and 2μL of template cDNA sup-
plemented with RNase-free water to a ﬁnal volume of
20μL. Primers were positioned to span exon-intron bound-
aries, reducing the risk of detecting genomic DNA. Each
PCR consisted of 10min at 95◦C for enzyme activation,
followed by 50 cycles of denaturation at 95◦Cf o r1 5 s
and annealing/extension at 60◦C for 1min. Negative con-
trol (RNA with no reverse transcription) was included
to control for DNA contamination. The housekeeping
gene glyceradehyde-3-phosphate dehydrogenase (GAPDH:
Assay ID Hs99999905 m1) was used as an endogenous
control. Expression values of nephronectin (NPNT) (Assay
ID Hs00405900 m1) and malectin (MLEC) (Assay ID
Hs00207082 m1) were normalized against the GAPDH
valuesforeachsample.Eachsamplewasrunintriplicate,and
the means were used in semiquantitative analysis.
2.6. Immunohistochemical Study. Immunohistochemical
analysis using the DAKO EnVision system (DAKO, Car-
pinteria, CA) was performed. Each sample was studied using
H-E staining and immunohistochemical staining. Frozen
sections were ﬁxed for 30min in 4% paraformaldehyde and
100 462 36
PTC Normal
562 498
Total identiﬁed protein: 598
Figure 1:Venndiagramofidentiﬁedproteins.InPTC,562proteins
were identiﬁed, and 498 were identiﬁed in normal thyroid tissue,
with 462 proteins being common to both PTC and normal thyroid
tissue. The total number of identiﬁed proteins was 598 (Normal;
normal thyroid tissue; PTC; Papillary thyroid carcinoma).
were washed with phosphate-buﬀered solution (PBS, pH
7.4) three times for 3min each. Blocking reagent (DAKO)
was then applied at room temperature for 10min in order
to prevent nonspeciﬁc binding of antibodies, and sections
were washed in PBS three times for 3min each. In this study,
anti-MLEC rabbit polyclonal (Sigma-Aldrich Inc., St. Louis,
MO) and Anti-POEM/NPNT rabbit polyclonal (Trans Genic
Inc., Kobe, Japan) antibodies were used. Antibodies were
diluted 200× and were dropped onto sections for 60min at
room temperature. Sections were incubated with polymer
reagent (DAKO EnVision) for 30min. After washing with
PBS, sections were incubated with 3,3 -diaminobenzidine
tetrahydrochloride (DAKO) for 1-2min. Finally, sections
were washed with distilled water, counterstained with
hematoxylin for 1min, washed with tap water and ethanol,
and covered with cover slips.
2.7. Statistical Analysis. A l lv a l u e sa r ee x p r e s s e da sm e a n s±
SD. The statistical signiﬁcance of diﬀerences between groups
was analyzed by unpaired Student’s t-test. A P value of less
than 0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Protein Identiﬁcation by LC/MS/MS. Protein identiﬁ-
cation results for triplicate injections were merged and
proteins detected twice or more were studied. In PTC and
normal thyroid tissue, the numbers of proteins were 562
and 498, respectively, and 462 proteins were common to
both. Thus, 100 proteins were unique to PTC, and 36
to normal thyroid tissue (Figure 1). Among the identiﬁed
proteins in both tissue types, several known markers and
two new markers (NPNT and MLEC), with large numbers of
NSAF, are shown in Figure 2. Previous studies indicated that
Keratin 19 (K1C19) and Dipeptidyl peptidase 4 (DPP4) were
strongly expressed in PTC, and Fatty acid-binding protein
4 (FABP4) was strongly expressed in normal thyroid tissues4 Journal of Thyroid Research
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Figure 2: Comparison of NSAF in the identiﬁed proteins in PTC
tissues(n = 3)withNSAFinnormalthyroidtissues(n = 3).Similar
to previous reports, Keratin 19 (K1C19) and Dipeptidyl peptidase
4 (DPP4) were strongly expressed in PTC, and Fatty acid-binding
protein 4 (FABP4) was strongly expressed in normal thyroid tissues.
NPNT and MLEC were discovered as strongly expressed candidate
markers in PTC (Normal: normal thyroid tissue, PTC: Papillary
thyroid carcinoma, ND: not detectable).
[12]. These observations suggest that our results reﬂect
characteristics unique to each type of membrane, as well as
common features between the three. As shown in Figure 2,
twonewcandidatemarkers,NPNTandMLEC,werestrongly
expressed in PTC.
3.2. Gene Expression of NPNT and MLEC in PTC and
Normal Thyroid Tissues. In order to conﬁrm the validity
of the LC/MS/MS results, semiquantitative real-time PCR
was performed with a set of human-speciﬁc primers and
template cDNA generated by reverse transcription. Similarly
to the LC/MS/MS results and previous reports, the levels of
K1C19 and DPP4 expression in the PTC were signiﬁcantly
higher than in normal thyroid tissue, while FABP4 levels
werelower(Figure 3).Withregardtonewcandidatemarkers,
although the levels of NPNT expression were signiﬁcantly
higher in PTC, there were no signiﬁcant diﬀerences in MLEC
expression (Figure 4).
3.3. Immunohistochemical Analysis of NPNT and MLEC in
PTC and Normal Thyroid Tissues. The distribution of NPNT
and MLEC protein expression in normal thyroid tissue
and PTC was examined by immunohistochemical analysis.
Few positive reactions for NPNT and MLEC were observed
in the follicular epithelium (surrounding tumor); on the
other hand, carcinoma cells were strongly stained (Figure 5).
Particularly for MLEC, no signiﬁcant diﬀerences in gene
expression were observed between normal thyroid tissue
and PTC; nevertheless, the protein localization was clearly
diﬀerent.
4. Discussion
MS-based proteome analysis of frozen tissue sections has
identiﬁed thousands of unique proteins in various histologi-
cal tissue samples. The results presented herein demonstrate
that a protein solubilization methodology allows global
proteomic investigation of tissues. In the present study using
our proteome platform, we identiﬁed two new markers for
PTC, NPNT and MLEC, as well as several known markers,
such as KRT19 and DPP4, with signiﬁcantly increased
expression in tissue samples from PTC.
PreOsteoblast EGF-like repeat protein with MAM
domain (NPNT) was originally identiﬁed in developing
mouse organs, particularly at epithelial-mesenchymal inter-
faces in tissues undergoing morphogenesis [13, 14]. The
proteinwasdeterminedtobeassociatedwithcellsorwiththe
extracellular matrix but was not found in culture medium,
leading to the hypothesis that NPNT is a matrix protein
binding to the cell surface. This agrees with an arg-gly-asp
binding domain and an integrin binding site found in the
amino acid sequence, as well as with a study showing that
integrin α-8 β-1 binds to NPNT [14]. Binding to other
integrin molecules has not speciﬁcally been observed to
date. In a recent study by Eckhardt et al., NPNT was ﬁrst
suggested to be involved in cancer [15]. They applied a
genomic analysis to cell lines derived from a spontaneous
breast cancer model in mice, and NPNT expression was
shown to be related to metastasis. In breast cancer, strong
NPNT expression was found in the tumor epithelium of
high-metastasis tumors.
MLEC is a novel carbohydrate-binding protein in the
endoplasmic reticulum (ER) and is a candidate player in
the early steps of protein N-glycosylation [16]. The recent
discovery of MLEC, an ER-resident protein that binds
oligosaccharides displaying terminal glucose residues with a
strong preference for di-glycosylated residues in vitro [16–
18], led to speculation on the possible involvement of this
lectin in the calnexin chaperone system and in glycoprotein
qualitycontrolinthemammalianER[19,20].Recently,Galli
et al. [21] showed that MLEC is an ER stress-induced type I
membrane protein that is associated with newly synthesized
glycoproteins in living cells. Analysis of the inﬂuenza virus
HA revealed that calnexin and MLEC have distinct kinetics
in association with newly synthesized polypeptides and
that MLEC is preferentially associated with misfolded HA
conformers[21].ChangesintheintraluminallevelsinMLEC
did not aﬀect the function of the calnexin chaperone system
or the maturation of HA, an obligate calnexin substrate
[21]. It is, therefore, unlikely that MLEC participates in the
calnexin chaperone system [21].
There are three main limitations to the present study.
The ﬁrst involves the intrinsic limitations of LC/MS in the
analysisofcomplexproteinmixtures.Proteinsofveryhighor
low molecular mass are frequently eliminated from analysis
by the electrophoresis procedure itself. Conversely, even after
depletion of very abundant proteins, both detection by LC
and identiﬁcation by MS are limited by the abundance of
the proteins in the mixture, and minor components will
always escape analysis. Therefore, candidates proteins atJournal of Thyroid Research 5
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Figure 3: Gene expression of previously known markers (K1C19, DPP4, and FABP4) in normal thyroid tissue and PTC. Gene expression
levels of K1C19 and DPP4 were signiﬁcantly higher in PTC when compared with normal thyroid tissue. In contrast, FABP4 expression was
lower (Normal: normal thyroid tissue, PTC: Papillary thyroid carcinoma, ∗P<0.05, Bar: 1 SD).
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Figure 4: Gene expression of new candidate markers (NPNT and
MLEC) in normal thyroid tissue and PTC. Gene expression of
NPNTwassigniﬁcantlyhigherinPTCwhencomparedwithnormal
thyroid tissue. However, expression of MLEC showed no signiﬁcant
diﬀerences (Normal: normal thyroid tissue, PTC: Papillary thyroid
carcinoma, ∗P<0.05, NS: not signiﬁcant, Bar: 1 SD).
picogram levels cannot be identiﬁed. The second limitation
pertains to the rigorous selection of membrane samples,
which does not allow the inclusion of an ample set of
samples and may consequently impede the consideration
of other candidate proteins existing in the tissues of PTC
patients. However, although the number of samples included
in this study was low, the selection process enabled us
to minimize the dispersion of the measurements in each
group. The observed diﬀerences by LC/MS were further
validated by RT-PCR analysis of samples from diﬀerent
patients, which conﬁrmed the observed diﬀerences with
good quantitative agreement. Therefore, although additional
diﬀerentially expressed proteins could probably be identiﬁed
by analyzing a larger set of samples, those reported herein
would likely also be found. Another limitation is that our
data does not demonstrate whether NPNT and MLEC cause
PTC, or are simply over-expressed due to tissue proliferation
in PTC. Moreover, apparently contrasting data (proteomic
analysis and IHC on one side, gene expression on the other
side) for malectin are shown, while for nephronectin they
are all concordant. This discrepancy may be due to protein
variants or posttranslational modiﬁcations that aﬀect the
tumor biology. Further studies are necessary in order to
elucidate whether NPNT and malectin play a role in the
etiology of PTC.
5. Conclusions
Recent advances in proteomic technologies are increasingly
being applied to the study of clinical samples in the search
fordiagnosticbiomarkersandtherapeutictargets.Herein,we
demonstrated that the powerful combination of LC/MS/MS
and frozen tissue samples, for which matching clinicopatho-
logicalinformationisavailable,isbeginningtoshowpromise
as a research tool. Using this method, we may thus be able
to identify new markers that cannot be distinguished on
gene expression analysis. Although the number of samples
included in this study was low, these data suggest that NPNT
and MLEC are characteristic markers and therapeutic targets
for PTC.6 Journal of Thyroid Research
Normal PTC
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Magniﬁcation: 100
Figure 5: Immunohistochemical localization of NPNT and MLEC in normal thyroid tissue and PTC. Only weak staining of NPNT and
MLEC were observed in follicular epithelium of normal thyroid tissue (surrounding tumor). In PTC, strong staining was seen with both
antibodies (Normal: normal thyroid tissue, PTC: Papillary thyroid carcinoma).
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